{"id":"ttax01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TTAX01 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, but the exact molecular details of TTAX01 are not well understood.","oneSentence":"TTAX01 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:06.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04450693","phase":"PHASE3","title":"Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)","status":"COMPLETED","sponsor":"BioTissue Holdings, Inc","startDate":"2020-11-20","conditions":"Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer","enrollment":106},{"nctId":"NCT04176120","phase":"PHASE3","title":"Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)","status":"COMPLETED","sponsor":"BioTissue Holdings, Inc","startDate":"2020-07-01","conditions":"Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer","enrollment":220},{"nctId":"NCT03230175","phase":"PHASE2","title":"Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)","status":"COMPLETED","sponsor":"BioTissue Holdings, Inc","startDate":"2017-10-04","conditions":"Non-healing Wound, Non-healing Diabetic Foot Ulcer, Diabetic Foot Infection","enrollment":32},{"nctId":"NCT03818828","phase":"PHASE2","title":"Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)","status":"COMPLETED","sponsor":"BioTissue Holdings, Inc","startDate":"2019-02-14","conditions":"Venous Leg Ulcer","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TTAX01","genericName":"TTAX01","companyName":"BioTissue Holdings, Inc","companyId":"biotissue-holdings-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"TTAX01 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}